Core Viewpoint - The resurgence of virus threats, particularly bird flu, has prompted increased interest in various treatment solutions, including those beyond vaccine development, with Aethlon Medical, Inc. at the forefront of innovative therapeutic approaches [1][2]. Company Developments - Aethlon Medical, Inc. is advancing its Hemopurifier® technology, which targets cancer-promoting exosomes and circulating viruses, and is preparing for phase 1 clinical trials focused on patients with solid tumors undergoing anti-PD-1 therapy [2][3]. - The Hemopurifier® has received FDA designation as a "Breakthrough Device" for treating advanced or metastatic cancer and life-threatening viral infections that lack approved therapies [3][4]. - Aethlon has previously explored the Hemopurifier®'s application in treating viral diseases, demonstrating its capability to capture various viruses, including HIV, hepatitis-C, and Ebola, in early studies [4]. Industry Trends - The current climate of heightened virus threats has led to a surge in interest from retail investors in stocks related to vaccine development, as evidenced by rising shares of vaccine manufacturers amid discussions of new vaccine programs for bird flu [5][9]. - ImmunityBio is also making strides in immunotherapy, with promising preclinical data suggesting that their combination therapy could manage HIV without the need for antiretroviral treatment [6][7]. - Aligos Therapeutics has reported positive results from its clinical trials for hepatitis B, showcasing complete suppression of HBV DNA in all subjects treated with their drug [8]. Market Sentiment - The increasing cases of bird flu are driving retail investors to seek out stocks with potential solutions, indicating a pattern of trading frenzies in response to emerging viral threats [9].

Group 1 - Aethlon Medical (NASDAQ:AEMD) stock is experiencing significant trading activity, with over 26 million shares exchanged, a substantial increase from its average daily volume of approximately 974,000 shares [1] - The company's float is around 2.56 million shares, indicating a limited supply available for trading [1] - AEMD is classified as a penny stock, with a prior closing price of 44 cents per share and a market capitalization of about $2.228 million [1] Group 2 - AEMD stock has surged by 82.4% as of Thursday morning, but it was down 79.8% year-to-date before this increase [2] - The lack of news or analyst coverage raises concerns about potential market manipulation, as penny stocks are often subject to "pump and dump" schemes [2] - Investors are advised to be cautious about investing in AEMD stock due to the volatility and the nature of penny stocks [2]

Core Insights - The global blood purification equipment market is projected to grow from USD 17,755.6 million in 2021 to USD 29,242.21 million by 2030, indicating significant market potential for companies in this sector [1]. Company Updates - Aethlon Medical, Inc. is advancing its Hemopurifier® device, which is designed to deplete cancer-promoting exosomes and circulating viruses. The FDA has designated it as a "Breakthrough Device" for treating advanced or metastatic cancer [3][4]. - Aethlon Medical is preparing for phase 1 clinical trials in Australia and India, targeting oncology patients with solid tumors who are not responding to anti-PD-1 monotherapy treatments like Keytruda® or Opdivo® [2][4]. - The company has integrated new in vitro data showing the Hemopurifier's ability to remove exosomes from cancer patient plasma into its clinical trial documentation, which is currently under review by Ethics Committees [2][4]. Financial Performance - CytoSorbents Corporation reported a 14% year-over-year increase in product sales for Q1 2024, reaching USD 9.0 million, the highest in nearly three years. The company also improved its product gross margins to 76% [5]. - Cerus Corporation reiterated its full-year 2024 product revenue guidance range of USD 172 million to USD 175 million, highlighting its ongoing progress in clinical milestones and commercial growth [6][7]. Industry Trends - The blood purification technology sector is gaining attention due to its potential applications in treating various diseases, including cancer and viral infections. Companies like Aethlon Medical are exploring the use of their devices in both oncology and viral disease treatments [11]. - The demand for innovative blood purification solutions is expected to rise, driven by global health challenges and the need for effective treatments against life-threatening conditions [11].

Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee ReviewSAN DIEGO, June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update ...

Core Viewpoint - Aethlon Medical, Inc. has announced a public offering of 8,100,000 shares of common stock and accompanying warrants, priced at $0.58 per share, aiming to raise approximately $4.7 million for general corporate purposes, including clinical trials and research and development [1][2]. Group 1: Offering Details - The public offering includes 8,100,000 shares of common stock and Class A and Class B warrants, all priced at $0.58 per share [1]. - Class A warrants will expire five years after issuance, while Class B warrants will expire one year after issuance [1]. - The offering is expected to close around May 17, 2024, pending customary closing conditions [1]. Group 2: Financial Proceeds - Gross proceeds from the offering are anticipated to be approximately $4.7 million before deducting fees and expenses [2]. - The net proceeds will be utilized for general corporate purposes, which may encompass clinical trial expenses, research and development, capital expenditures, and working capital [2]. Group 3: Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [5]. - The Hemopurifier has shown promise in removing life-threatening viruses and harmful exosomes in clinical and pre-clinical studies [5]. - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [5].

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on May 13, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Name, address, including zip code, and telephone number, including area code, of agent for service) (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO, May 10, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from p ...

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on April 25, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Id ...

Table of Contents Registration No. 333-278188 As filed with the Securities and Exchange Commission on April 5, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Ide ...

Table of Contents Registration No. 333- As filed with the Securities and Exchange Commission on March 22, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 1155 ...